Grade My Investments
HomeFree Stock Grades › DTIL

Precision BioSciences, Inc. (DTIL) Stock Grade

DTIL · Healthcare

D+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$53.4M
P/E Ratio
Revenue Growth (YoY)
-50.1%
Net Margin
-133.5%
Return on Equity
Dividend Yield
None

About Precision BioSciences, Inc.'s fundamentals

Precision BioSciences is a small-cap biotechnology company with a market capitalization of $53.4 million that is currently unprofitable, reporting a net loss in its latest annual statement and a net margin of -133.5%. The company experienced significant revenue contraction, declining 50.1% year-over-year, indicating a substantial pullback in its business operations. As a pre-profitability biotech firm with no dividend, the company is in a development or clinical stage where financial performance metrics like P/E ratio and return on equity are not meaningful.

Track DTIL free — no credit card required. Live grade + monthly AI report →